Passage Bio announces $70 million private placement at $1.39 per share, including pre-funded warrants
PASG•Passage Bio announces $70 million private placement tied to planned merger
Passage Bio disclosed a $70 million private placement tied to its planned merger with Remix Therapeutics.
Accredited investors will buy Remix common stock or pre-funded warrants at $1.39 per share or $1.39 per warrant.
The financing is set to close immediately before the first step of the merger, subject to deal conditions.
